Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) — The “Liposomal Drug Delivery Devices Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering.
The global liposomal drug delivery devices market is expected to grow from $3.72 billion in 2021 to $4.10 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The market is expected to grow to $6.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%.
North America was the largest region in the liposomal drug delivery devices market in 2021. Asia Pacific was the second-largest region in the liposomal drug delivery devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in radiation therapy, chemotherapy, and surgical resection. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the liposomal drug delivery devices market over…
